Screened 2026-09-09 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Okta, Inc. holds its Markup at $172.74. Consolidating, no directional conviction, held for 9 days.
As held on the ledger · 2026-09-09
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 9 days
Price at the screen
$172.74
Valuation
104.06 trailing · 39.45 forward price to earnings
Values screen
PASS
Beta
0.79
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.79%
Below 33%
Interest-bearing debt is just 2.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
15.78%
Below 33%
Cash held in interest-bearing accounts and securities is 15.8% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. The price runs 12.9% above the base estimate.
Third-party analyst targets: 43 covering, consensus Buy. The average target sits +8% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Login Software Priced Far Above Its Numbers
Picture a worker logging into half a dozen apps each morning. Okta sits in the middle of that flow, yet the business now grows revenue at just 11 percent while posting an 8 percent profit margin and 4 percent return on equity.
We pass. The shares trade at 34.9 times forward earnings against a weak moat and a fair value well below the current price, leaving no cushion even though the ethical screen is clear.
Analysts still lean buy, but that consensus target sits below where the stock trades today. Slowing growth plus thin returns at this valuation is the classic setup for disappointment. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
OKTA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup · changed$135.14+0.0%Entry 11
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Distribution$135.14+0.0%Entry 10
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Distribution$135.14+0.0%Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Distribution$135.14-5.8%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.8% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-21Distribution$143.51+0.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-20Distribution$143.51+0.0%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-07Markup$143.51+20.9%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102.
2026-07-18Markup$118.72+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (44 analysts) rates it buy, with a mean price target of $102.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
